Medidata Solutions (NASDAQ:MDSO) had its target price hoisted by research analysts at Needham & Company LLC to $80.00 in a research note issued on Friday. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price objective suggests a potential upside of 9.38% from the stock’s previous close.
Several other equities analysts also recently issued reports on MDSO. Zacks Investment Research raised shares of Medidata Solutions from a “sell” rating to a “buy” rating and set a $74.00 price objective on the stock in a report on Tuesday, April 17th. ValuEngine raised shares of Medidata Solutions from a “sell” rating to a “hold” rating in a report on Thursday, April 12th. BidaskClub raised shares of Medidata Solutions from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. TheStreet raised shares of Medidata Solutions from a “c+” rating to a “b-” rating in a report on Monday, March 12th. Finally, Royal Bank of Canada set a $82.00 price objective on shares of Medidata Solutions and gave the company a “hold” rating in a report on Thursday, February 8th. Four research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $82.71.
MDSO opened at $73.14 on Friday. The company has a current ratio of 1.63, a quick ratio of 1.49 and a debt-to-equity ratio of 0.18. The firm has a market cap of $4,351.27, a price-to-earnings ratio of 86.05, a P/E/G ratio of 3.86 and a beta of 1.53. Medidata Solutions has a 52-week low of $59.60 and a 52-week high of $85.92.
Medidata Solutions (NASDAQ:MDSO) last posted its quarterly earnings data on Thursday, April 19th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.35 by $0.05. The business had revenue of $149.20 million for the quarter, compared to the consensus estimate of $146.73 million. Medidata Solutions had a net margin of 7.96% and a return on equity of 11.36%. The company’s revenue was up 16.9% compared to the same quarter last year. During the same period last year, the firm posted $0.31 earnings per share. research analysts anticipate that Medidata Solutions will post 0.94 earnings per share for the current fiscal year.
In other news, CFO Rouven Bergmann sold 3,000 shares of the stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $70.00, for a total value of $210,000.00. Following the completion of the sale, the chief financial officer now directly owns 84,775 shares in the company, valued at $5,934,250. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Tarek Sherif sold 26,836 shares of the stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $70.25, for a total transaction of $1,885,229.00. The disclosure for this sale can be found here. Insiders sold 37,836 shares of company stock valued at $2,648,769 over the last quarter. Company insiders own 5.80% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Medidata Solutions by 48.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,242 shares of the company’s stock valued at $205,000 after buying an additional 1,056 shares during the last quarter. Meadow Creek Investment Management LLC raised its position in shares of Medidata Solutions by 31.4% in the fourth quarter. Meadow Creek Investment Management LLC now owns 3,680 shares of the company’s stock valued at $233,000 after buying an additional 880 shares during the last quarter. Polen Capital Management LLC raised its position in shares of Medidata Solutions by 77.0% in the fourth quarter. Polen Capital Management LLC now owns 4,640 shares of the company’s stock valued at $294,000 after buying an additional 2,018 shares during the last quarter. Brown Advisory Securities LLC acquired a new stake in shares of Medidata Solutions in the fourth quarter valued at about $356,000. Finally, Elkfork Partners LLC acquired a new stake in shares of Medidata Solutions in the fourth quarter valued at about $408,000.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/22/needham-company-llc-increases-medidata-solutions-mdso-price-target-to-80-00.html.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.